Appropriate use of PCSK9 Inhibitors in India

Area of Science:

• Cardiology
• Metabolic Disorders

Background:

• Atherosclerotic cardiovascular disease (CVD) poses a significant and growing health burden.
• Dyslipidemia is a primary modifiable risk factor for CVD, identified as the leading contributor to myocardial infarction by the INTERHEART study.

Purpose of the Study:

• To highlight the critical role of low-density lipoprotein cholesterol (LDL-C) as a therapeutic target in managing dyslipidemia.
• To discuss the limitations of current LDL-C lowering therapies, including statins and ezetimibe, in achieving treatment goals or in cases of poor drug tolerance.

Main Methods:

• Review of existing literature on dyslipidemia management and cardiovascular disease.
• Analysis of the impact of dyslipidemia on myocardial infarction risk.
• Evaluation of the efficacy and tolerability of current therapeutic lifestyle changes, statins, and ezetimibe.

Main Results:

• Dyslipidemia significantly contributes to the risk of myocardial infarction.
• Statins and ezetimibe are effective in lowering LDL-C and improving cardiovascular outcomes.
• Challenges remain in achieving target LDL-C levels or managing drug-intolerant patients.

Conclusions:

• Effective management of dyslipidemia is crucial for reducing the burden of atherosclerotic cardiovascular disease.
• While current therapies are beneficial, alternative or adjunctive strategies may be needed for specific patient populations.
• Further research into novel therapeutic approaches for dyslipidemia is warranted.